Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated:  12/10/2013
1218.74.01045 Boehringer Ingelheim Investigational Site
mi
from
Rockville, MD
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated: 12/10/2013
1218.74.01045 Boehringer Ingelheim Investigational Site
mi
from
Rockville, MD
Click here to add this to my saved trials
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated:  12/10/2013
1222.52.02030 Boehringer Ingelheim Investigational Site
mi
from
Marlton, NJ
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated: 12/10/2013
1222.52.02030 Boehringer Ingelheim Investigational Site
mi
from
Marlton, NJ
Click here to add this to my saved trials
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated:  12/10/2013
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated: 12/10/2013
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated:  12/10/2013
205.452.01001 Boehringer Ingelheim Investigational Site
mi
from
Salt Lake City, UT
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated: 12/10/2013
205.452.01001 Boehringer Ingelheim Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
UCLA-Amity Parolee Health Promotion Study
Health Promotion Coaching/Vaccine for Homeless Parolees
Status: Enrolling
Updated:  1/8/2014
Amistad de Los Angeles
mi
from
Los Angeles, CA
UCLA-Amity Parolee Health Promotion Study
Health Promotion Coaching/Vaccine for Homeless Parolees
Status: Enrolling
Updated: 1/8/2014
Amistad de Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Goodyear, AZ
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Phoenix, AZ
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Bakersfield, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Chula Vista, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Long Beach, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
San Bernardino, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
San Bernardino, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Ventura, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Ventura, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Miami, FL
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Miami, FL
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Springfield, IL
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Louisville, KY
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Pikeville, KY
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Pikeville, KY
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Baltimore, MD
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Kansas City, MO
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Kansas City, MO
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
St. Louis, MO
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
New York, NY
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Cleveland, OH
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Portland, OR
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Fort Worth, TX
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Houston, TX
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Norfolk, VA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
mi
from
Richmond, VA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
mi
from
New Orleans, LA
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
mi
from
Baltimore, MD
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
mi
from
Novi, MI
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
mi
from
Novi, MI
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
mi
from
Kansas City, MO
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
mi
from
Flushing, NY
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
mi
from
Flushing, NY
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
mi
from
Limerick, PA
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
mi
from
Limerick, PA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Dumont-UCLA Liver Transplant Center
mi
from
Los Angeles, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Dumont-UCLA Liver Transplant Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Huntington Medical Research Institutes
mi
from
Pasadena, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Huntington Medical Research Institutes
mi
from
Pasadena, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Kaiser Permanente
mi
from
Sacramento, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Kaiser Permanente
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Kaiser Permanente
mi
from
San Diego, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Kaiser Permanente
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Kaiser Permanente
mi
from
San Francisco, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Kaiser Permanente
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Silicon Valley Research Institute
mi
from
San Jose, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Silicon Valley Research Institute
mi
from
San Jose, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
University of Miami
mi
from
Miami, FL
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Northwestern Memorial Hospital
mi
from
Chicago, IL
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Digestive Disease Associates, PA
mi
from
Baltimore, MD
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Digestive Disease Associates, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Tufts Medical Center
mi
from
Boston, MA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
University of Michigan
mi
from
Ann Arbor, MI
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials